It appears as if Democrat and Republican lawmakers wanted to avoid any politically charged add-ons with the upcoming US FDA user fee program reauthorizations, as several topics that have received congressional attention were left out of the Senate Health, Education, Labor and Pensions (HELP) Committee’s manager's package.
Senate's User Fee Bill Largely Steers Clear Of Controversy
HELP Committee manager’s amendment lacks provisions on such hot-button issues as off-label drug promotion, REMS abuses and right-to-try legislation.
More from Legislation
More from Pink Sheet
• By
A professional slide deck for the drospirenone/estetrol oral contraceptive inappropriately suggests it is safer than other estrogen-containing products and understates risks, Office of Prescription Drug Promotion said in the first “untitled” letter issued since reductions-in-force.
• By
Silicon Valley investor Jim O’Neill’s Senate confirmation hearings showcased the unique background of someone with government and tech experience and avoided discussions of his past statements about lowering the bar for regulatory approval.
• By
The FDA continues to wait for a decision on whether its priority guidances will be published as HHS asks the public for potential regulation cuts to fulfill President Trump’s executive order.